Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...
medicines for diabetes and cardiovascular diseases; and established prescription products. Receive News & Ratings for Sanofi ...
Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...
(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Cardiovascular disease is a group of conditions that affect your heart and blood vessels. It's sometimes also called heart disease. Conditions that affect your heart and blood vessels can include ...
Heart Pieces and Heart Containers are a staple in The Legend of Zelda series, and they're back in Echoes of Wisdom, serving the same purpose as always. With lots of Heart Pieces to collect to make ...
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback